Recent News

• 02.19.2026 - STRATA Skin Sciences Confirms Nasdaq Delisting
• 02.18.2026 - Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser
• 02.17.2026 - STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis
• 12.09.2025 - STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico
• 11.13.2025 - STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
• 11.06.2025 - STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion
• 11.05.2025 - STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update
• 10.28.2025 - STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements
• 10.20.2025 - STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek

Recent Filings

• 02.19.2026 - 25 Notification of the removal from listing and registration of matured, redeemed or retired securities
• 02.11.2026 - 8-K Current report
• 12.17.2025 - 8-K Current report
• 12.17.2025 - EX-99.1 EX-99.1
• 12.10.2025 - 8-K Current report
• 11.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.13.2025 - 8-K Current report
• 11.13.2025 - EX-99.1 EX-99.1
• 11.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors